Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
Woman-Health Focused Stock Agile Therapeutics Is ‘Better Positioned,’ Analyst Says While Upgrading Stock
Maxim Group upgraded Agile Therapeutics Inc (NASDAQ:AGRX) to Buy from Hold with a price target of $1, saying it should be…
Seagen’s Bladder Cancer Trial Data Meets Expectation, Analysts Say
Earlier today, Seagen Inc (NASDAQ:FBI) and Astellas Pharma Inc (OTC:ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev…
Aurinia Pharmaceuticals Receives Notice Regarding USPTO Trial And Appeal Board Decision To Institute Trial On Inter Partes Review Filed By Sun Pharmaceuticals
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development
Reneo Pharmaceuticals Inc (NASDAQ:RPHM) has reported results from the REN001 long-chain fatty acid oxidation disorders (LC-FAOD) study and provided additional development…
Virax Biolabs Introduces Monkeypox And Varicella-Zoster Viruses Real-Time PCR Detection Kit
Virax Biolabs Group Limited (“Virax” or the “Company”) (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched
Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol
- ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023